Novel fully human high-affinity anti-TREM2 antibody shows efficacy in clinically relevant Alzheimer´s mouse model
Compared to existing humanized anti-hTREM2 antibodies that have been investigated in clinical trials, M07-TFN showed best-in-class affinities and agonist potencies. Being a fully human anti-hTREM2 antibody, M07-TFN holds the promise of reduced immunogenicity for use in human patients.
Authors
- Joseph Kroeger
- Bastian Popper (ORCID: https://orcid.org/0000-0003-1517-695X)
- Barbara Fink
- Ammar Jabali (ORCID: https://orcid.org/0000-0002-2772-8531)
- Julia Faßbender
- Markus Kraller
- Martin Ungerer (ORCID: https://orcid.org/0000-0002-2811-4283)
- Miriam A. Christlmeier
Institutions
- Bioscience Research (US)
- Urologische Klinik München (DE)
- Ludwig-Maximilians-Universität München (DE)
Publication Details
- Journal
- Alzheimer s Research & Therapy
- Published
- 2025-05-22
- DOI
- https://doi.org/10.1186/s13195-025-01759-x
- Citations
- 4
- Primary Topic
- Inflammation biomarkers and pathways
- Type
- article
- Field-Weighted Citation Impact
- 3.19
Funders
- Bundesministerium für Bildung und Forschung